Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide

NCT03152318 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT03152318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03152318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 18, 2017
Completion date
January 31, 2028
Enrollment
62 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic oligodendroglioma of brain (diagnosis), astrocytoma, brain cancer, brain tumor, ependymoma, ganglioglioma, glioblastoma, glioblastoma multiforme, glioma, malignant astrocytoma, malignant glioma of brain, mixed oligo-astrocytoma, oligodendroglioma, pylocytic/pylomyxoid astrocytoma